CHEPP方案治疗T细胞淋巴瘤临床观察

目的比较CHOP方案与CHEPP方案治疗T细胞非霍奇金淋巴瘤的疗效和不良反应。方法采用两种方案治疗T细胞非霍奇金淋巴瘤患者65例,CHOP组35例,CHEPP组30例。结果两组患者临床特征指标相似（P〉0.05）。两组有效率分别为54.2%和80%,CR率分别为22.9%和53.3%（P〈0.01）。骨髓抑制、胃肠道反应、脱发为主要不良反应。骨髓抑制CHEPP组明显高于CHOP组（73.3%,34.3%,P〈0.01）。胃肠道反应CHEPP组明显高于CHOP组（80%,40%,P〈0.05）。两组2年无瘤生存率CHEPP组明显高于CHOP组（56.7%,17.1%,P〈0.01）。结论CHEPP方案治疗T细胞淋巴瘤疗效较好,远期生存率较高,值得临床进一步研究。

The Clinical Observation of CHEPP Regimen on Treating T-cell Lymphoma LI

Objective To compare the efficacy and toxicity of CHOP and CHEPP regimen in the treatment of T-cell non-Hodgkin lymphoma. Methods Apply two regimen to treat 65 cases of T-cell NHC patients. 35 cases were in CHOP group and 30 cases in CHEPP group. Results The clinical characteristics of the two groups were similar（P 〉 0. 05 ）. The response rate for CHOP and CTOP was 54. 2% and 80% , respectively and the CR rate was 22. 9% and 53.3% （ P 〈 0.01 ）. Major toxicity was myelosuppression, GI toxicity and alopecia. Incidence of myelosuppression in CHEPP group was higher than in CHOP group （73.3% ,34. 3% , P 〈 0. 01 ）. Incidence of GI toxicity in CHEPP group was higher than in CHOP group（80% ,40% ,P 〈0. 05）. The 2-year tumor-free survival rate was notably higher in CHEPPgroup than in CHOP group（56. 7% , 17. 1%. P 〈 0.01 ）. Conclusion CHEPP regimen may be more effective on treating T-cell lymphoma with better long term survival and it is wortlhy of further study of the clinical.